Key Takeaways
- Strong quarter, stronger Q4 expected: Consolidated revenue grew ~2% YoY to ₹651 cr, with 9M growth at ~9.3%. Management guided for a strong Q4 and "higher mid to higher teens" top-line growth in FY25.
- Notional FOREX loss masks operating health: A ₹76 cr non-cash charge from USD/CHF translation hit reported EBITDA, but part has already reversed as the pair moved back to ~0.8850. Excluding this, EBITDA was ₹119 cr vs ₹115 cr a year ago.
- The French facility is finally producing: GMP production was validated, released and delivered by end of Q3, with production planning full until end of summer. The site targets €7–8 mn in Q4 and ~€20 mn in FY25, at which point it should break even.
- Regulatory overhang cleared at Bavla: EDQM and AIFA certificates are now in place, reopening Europe (the largest market for India CRAMS) and enabling product transfers from Switzerland. India CRAMS revenue grew 21% in Q3 and is expected to grow in high double digits in FY25.
- What to watch next quarter: Whether the French facility hits its €7–8 mn Q4 target, the pace of wool grease price normalization, and any concrete FY25 guidance upgrade as new capacities (ADC, Bavla, France) begin contributing.
French Facility: From Overhang to Contributor
- Delayed start, now resolved: The drug product business had been delayed; GMP production was finalized, validated, released and delivered to customers by end of Q3. Production planning is now full until end of summer, with a large pipeline of quotations.
- Q4 revenue target: Management is targeting between €7 and €8 million in the current quarter.
- FY25 budget: The facility is budgeted at ~€20 million revenue for the next financial year, with breakeven at ~€17–18 million. Management expects it to be "a little bit in profit" at that revenue level.
- Segment reporting change: From next year, the French facility will be shown as a separate segment within Carbogen Amcis CRAMS as it becomes sizable.
- Longer-term ambition: The French entity is expected to grow exponentially over the next three to five years, with peak revenue of ₹40–45 crore.
Pascal Villemagne: "we finalized GMP production on that site which was validated, released and delivered to the customers."
Carbogen Amcis CRAMS: Pipeline at a Record High
- Revenue momentum: CRAMS revenue grew 9.4% in Q3 and 19% in 9M. The Q3 EBITDA margin of ~20% was down from 22.3% a year ago, which had benefited from a large commercial/Phase 3 supply.
- Pipeline at historical high: The current pipeline stands at ₹15 crore, a 50% increase from ₹9–10 crore two years back.
- ADC expansion qualified: The ADC molecule expansion in Switzerland is now qualified; production and revenues from that expansion will start in the next financial year.
- Swiss entity model: ~50% of Swiss revenues come from developmental work where the main input is human technical talent, making employee cost structurally high at 50–55% of the Swiss P&L. The entity is expected to grow 9–10% on a five-year view with margins of 20–22%.
- Molecule revenue unpredictability: Management declined to quantify revenue potential from newly commercialized or late-phase molecules, calling it "almost impossible to predict a number" because it depends on customers' market authorization.
Pascal Villemagne: "I would like to, I would love to, because that would make our life much more simpler, but it's almost impossible to predict a number."
India CRAMS: Regulatory Reset Complete
- Bavla site cleared: EDQM and AIFA certificates are now in place, with the EU GMP compliance certificate uploaded to EudraGMDP on February 2, 2024. Japanese PMDA approval was also received on January 23, 2024.
- Growth already visible: India CRAMS revenue grew 21% to ₹55.6 cr in Q3, with Q4 expected to be even stronger.
- FY25 outlook: Management expects India CRAMS to grow "at least in high double digits" in FY25 and to be "closer to pre-EDQM levels." An analyst's assessment of ₹300–350 crore revenue for FY25 was called "a fair assessment."
- ₹1,000 crore capacity without major CAPEX: India now has the capacity and capability to do revenue of close to ₹1,000 crores without any major CAPEX, driven by operational changes at Bavla and Naroda.
- Margin recovery path: India CRAMS EBITDA margin should be able to reach historical levels of close to 40%, though the cost base has increased from three to four years back because of increased compliance at both Bavla and Naroda sites.
Sanjay Majumdar: "the cost base has increased because of the increased compliances that we have put in place both at the Bavla site and the Naroda site. So, yes, the cost base has increased from what it was three-and-a-half, four years back."
Vitamin D Analogues & Cholesterol: Margin Squeeze from Wool Grease
- Conscious volume pullback: Q3 revenue dipped to ₹61 cr from ₹82.5 cr a year ago due to lower cholesterol sales, a deliberate decision because of increased wool grease prices. 9M revenue still grew 14.6%.
- Margin impact: EBITDA margin fell to 16.6% in Q3 and 15% in 9M, down from 18% in 9M FY23, driven by the wool grease price increase.
- Normalization expected: Wool grease prices are expected to normalize over the next quarter.
- Cost pass-through underway: The company is working on passing increased costs to customers, with a lag time ranging from two to four quarters, averaging annually depending on contract length and customer relationship.
Costs, Margins & the Employee Cost Question
- Employee cost jump largely currency-driven: The sharp QoQ and YoY increase in employee cost was largely from FX movement, with ~₹24 crore of the increase attributable to Swiss Franc translation alone.
- Swiss structural reality: 50–55% of the Swiss entity P&L is employee cost because Switzerland sells technical talent and must match salaries of Novartis and Roche. Management stated it would be "very difficult to reduce that cost from what the cost is currently."
- The offset strategy: As India and China (now profitable) revenues increase, employee cost as a percentage of revenue should decline, improving group EBITDA margins.
- Consolidated EBITDA target: Management aims to move to 24–25% at the consolidated level, with FY25 internally targeted at around 20% due to transition and the first full year of new facilities not at optimum operations.
- Historical precedent: The company previously delivered 20–25% EBITDA even with this high employee cost structure in a normalized situation.
- Piramal comparison deflected: When an analyst noted employee cost at ~40% of revenue is much higher than Piramal Pharma at ~27%, management said "I don't think everyone is directly comparable" and offered to take the discussion offline.
Harshil Dalal: "I mean, what we sell is the talent, is the technical capability that we have at the Swiss entity and that attracts our customers the most. What we are trying to do is to try and see how we could reprice the project as far as the development work is concerned. But it would be very difficult for us to reduce that cost from what the cost is currently."
Balance Sheet & Capital Allocation
- Notional FOREX explained: The ₹76 cr notional loss is from translating balance sheet cash balances in USD, EUR, GBP and CHF at closing exchange rates, with USD/CHF moving from 0.9156 to 0.8417. Part has already reversed as the pair moved back to ~0.8850. A prudent hedging policy with forwards and swaps is in place for revenues, costs and liabilities.
- ROCE distorted by goodwill and FX: Large goodwill from the 2017 merger and ~₹600 crore of FX impact embedded in fixed assets depress reported ROCE. Discounting these, ROCE was 15–16% in FY20/FY19, with an internal target to move toward 20–25% in the medium term and 30% in the long term.
- Deleveraging thesis: With no major CAPEX plans over the next three years, cash generation should reduce net debt. Management wants to get back to ~₹10–11 crore of Swiss Franc debt over three to four years.
- Interest cost peak: ₹33 crore per quarter can be taken as the peak interest cost. As USD LIBOR comes down from 5.5% and net debt decreases, interest cost should decline from ₹115 crore to ~₹60–65 crore in three to four years.
- Maintenance CAPEX: ₹16–17 crore per year across all entities. Growth CAPEX is not significant and would only be driven by customer projects with co-investment agreements.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated revenue growth | "Higher mid to higher teens" top-line growth | FY25 |
| Consolidated EBITDA growth | "Very considerably strong EBITDA growth" with normalization in almost all quarters | FY25 |
| Consolidated EBITDA margin | Internally targeted at ~20% (transition year); move to 24–25% thereafter | FY25 / medium term |
| French facility revenue | €7–8 mn in Q4; ~€20 mn budgeted for FY25 | Q4 FY24 / FY25 |
| French facility profitability | Breakeven at ~€17–18 mn; "a little bit in profit" at ~€20 mn | FY25 |
| India CRAMS growth | "At least high double digits"; closer to pre-EDQM levels | FY25 |
| India CRAMS revenue | ~₹300–350 crore called "a fair assessment" by management | FY25 |
| Wool grease prices | Expected to normalize | Next quarter |
| ADC molecule revenues | Production and revenues from Swiss ADC expansion to start | FY25 |
| Interest cost | Decline from ₹115 crore to ~₹60–65 crore | 3–4 years |
| Net debt (Swiss Franc) | Reduce to ~₹10–11 crore of CHF debt | 3–4 years |
| 3–5 year consolidated CAGR | Close to ~15% revenue CAGR; EBITDA growth "much higher than 12–15%" | 3–5 years |
| ROCE | Move toward 20–25% medium term, 30% long term | Medium / long term |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Consolidated revenue | ₹651 cr, +2% YoY |
| Consolidated revenue (9M FY24) | ₹1,961 cr, +9.3% YoY |
| EBITDA (excl. notional FOREX) | ₹119 cr, vs ₹115 cr in Q3 FY23 |
| EBITDA (excl. notional FOREX, 9M FY24) | ₹309 cr, vs ₹287 cr in 9M FY23 |
| Notional FOREX loss | ₹76 cr, driven by USD/CHF movement from 0.9156 to 0.8417 |
| Carbogen Amcis CRAMS revenue | ₹506 cr, +9.4% YoY |
| Carbogen Amcis CRAMS EBITDA margin (excl. notional FOREX) | ~20%, vs 22.3% in Q3 FY23 which had exceptionally high Phase 3 supply |
| Vitamin D analogues and cholesterol revenue | ₹61 cr, vs ₹82.5 cr in Q3 FY23; decline due to lower cholesterol sales and higher wool grease prices |
| India CRAMS revenue | ₹55.6 cr, +21% YoY |
| India CRAMS EBITDA margin | ~11% |
| India Quats and Generics EBITDA margin | ~7.5% |
| Net debt | ₹1,558 cr (INR), 15.8 cr Swiss Franc |
| Gross debt | ₹2,105 cr |
| Interest cost | ₹33 cr, stated as the peak quarterly run-rate |
| Capital expenditure (9M FY24) | ₹2.5 cr, expected ~₹3 cr by FY24 end |
| French facility Q3 revenue | €0.23 cr, with EBITDA loss of €0.14 cr |
| French facility Q4 FY24 revenue target | €7–8 million |
| French facility FY25 revenue budget | ~€20 million, with breakeven at ~€17–18 million |
| Carbogen Amcis CRAMS development pipeline | 15 cr (total orders in hand), a historical high and 50% increase over two years |
| Consolidated revenue CAGR target (3–5 year view) | ~15% |
| FY25 consolidated EBITDA margin target | ~20% |
| India CRAMS revenue target for FY25 | ₹300–350 cr (per an analyst's math, management confirmed as fair) |
| Employee cost increase due to FX (Q3 FY24 vs Q3 FY23) | ~₹24 cr |
| Swiss entity employee cost as percentage of Swiss P&L | 50–55% |
| Raw material cost as percentage of consolidated revenue | ~20% |
| Swiss revenue from developmental work | ~50% |